Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
EBIATOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Allarity Therapeutics (ALLR) Long-Term Debt Issuances (2024)

Allarity Therapeutics' Long-Term Debt Issuances history spans 1 years, with the latest figure at $1.3 million for Q1 2024.

  • For Q1 2024, Long-Term Debt Issuances changed N/A year-over-year to $1.3 million; the TTM value through Dec 2024 reached $1.3 million, changed N/A, while the annual FY2024 figure was $1.3 million, 27.62% up from the prior year.
  • Long-Term Debt Issuances reached $1.3 million in Q1 2024 per ALLR's latest filing.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $1.3 million in Q1 2024 to a low of $1.3 million in Q1 2024.